ArticleCancer immunology, immunotherapy : CII2022

The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents.

Carlos Zamora Atenza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.